GlassScriptPhysician profile
Kockyen Tsang
NPI 1821149741
$11,495.83
in general payments reported to CMS, 2019-2025
34 companies · $992 in 2025
The $992 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,590 · 2020: $1,103 · 2021: $1,962 · 2022: $1,744 · 2023: $3,050 · 2024: $1,055 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,998 · Travel and Lodging: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,998.00 |
| Travel and Lodging | $1,099.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,981.00 | 2019-2025 | Aveir, Jot Dx, Amplatzer Amulet |
| Boston Scientific Corporation | $2,119.64 | 2021-2025 | Watchman Access System, S-Icd System Magnet, Cds - Mct/Cem Monitoring |
| Janssen Pharmaceuticals, INC | $1,358.39 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $1,127.30 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $484.57 | 2019-2022 | |
| Pfizer INC. | $331.97 | 2019-2025 | |
| Amarin Pharma, INC. | $284.99 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $266.06 | 2023-2025 | Farxiga, Breztri, Lynparza |
| Novartis Pharmaceuticals Corporation | $236.00 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.10 | 2021-2024 | Jardiance |
| Medtronic, INC. | $148.82 | 2023-2025 | Symplicity G3, Micra |
| Atricure, INC. | $114.18 | 2020 | |
| Phathom Pharmaceuticals, INC. | $113.96 | 2025 | Voquezna |
| Stereotaxis INC | $96.24 | 2023 | Niobe |
| Actelion Pharmaceuticals US, INC. | $92.76 | 2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $92.14 | 2019 | |
| Abiomed | $71.34 | 2023-2024 | Impella |
| Heartflow, INC. | $47.69 | 2024 | |
| Cvrx, INC. | $44.64 | 2022-2023 | Barostim Neo System |
| Kiniksa Pharmaceuticals, LTD. | $32.39 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.84 | 2023 | Lifevest |
| Irhythm Technologies, INC. | $31.75 | 2024 | Zio Monitor, Zio Xt Patch |
| Merck Sharp & Dohme LLC | $28.47 | 2021-2023 | Verquvo |
| Scpharmaceuticals INC. | $23.35 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $23.33 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2023 | |
| Novo Nordisk INC | $16.53 | 2024 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $15.91 | 2023 | Evkeeza |
| Philips North America LLC | $15.26 | 2025 | Extended Holter |
| Edwards Lifesciences Corporation | $14.69 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.90 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.78 | 2019 | |
| Acarix USA INC. | $13.55 | 2024 | Cadscor System |
| Paratek Pharmaceuticals, INC. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kockyen Tsang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.